SpyGlass Pharma Rings the Nasdaq Stock Market Opening Bell
SpyGlass Pharma, Inc. (Nasdaq: SGP), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines, visits the Nasdaq MarketSite in Times Square.
In honor of the occasion, Patrick Mooney, Chief Executive Officer rings the Opening Bell.